PharmaCom BioVet, Inc.
PHMB
Other OTC0.00
USD
- -
- -
ISIN
US71720A1079
CUSIP
71720A107
Return %
Stock
S&P500
1Y
0.00
26.53
3Y
- -
76.60
5Y
- -
80.11
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Ira Frohman
- Sector
- Healthcare
- Industry
- Medical - Care Facilities
- Address
- 6040-A Six Forks Road Raleigh NC United States of America 27609
- IPO Date
- May 5, 1999
- Website
- pharmacombiovet.com
- Similar Companies
- Business
- PharmaCom BioVet, Inc. (PHMB) focuses on operating a network of companion animal cancer treatment centers in the United States, developing bone marrow transplantation procedures including autologous, allogeneic, and haploid transplants, and other cancer therapies for dogs and cats diagnosed with lymphoma, various cancers, and incurable diseases; it licenses proprietary devices and compounds to reduce animal suffering from cancer. The company, founded in 1995 as Bach-Hauser Inc. and formerly known as ABV Gold Inc., a gold mining entity, changed its name to PharmaCom BioVet, Inc. in August 2008 following a share exchange acquisition of PharmaCom BioVet LLC as a wholly owned subsidiary, a 1-for-15 reverse stock split, and an increase in authorized common shares from 350 million to 3 billion with 50 million preferred shares added; these restructuring actions supported a strategic shift from mining to veterinary oncology, including plans for canine bone marrow transplant centers at veterinary universities and a national canine DLA registry for donor matching. Headquartered at 6040-A Six Forks Road, Suite 135, Raleigh, North Carolina 27609, the company targets North American pet owners through partnerships with veterinary oncologists and hospitals, emphasizing compassionate care in a market where companion animal cancer treatments exceed $200 million annually; no recent partnerships, funding rounds, acquisitions, or new product launches occur within the last 1-2 years amid minimal operations and zero reported revenue.